176 related articles for article (PubMed ID: 27821605)
1. A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Yau TCC; Lencioni R; Sukeepaisarnjaroen W; Chao Y; Yen CJ; Lausoontornsiri W; Chen PJ; Sanpajit T; Camp A; Cox DS; Gagnon RC; Liu Y; Raffensperger KE; Kulkarni DA; Kallender H; Ottesen LH; Poon RTP; Bottaro DP
Clin Cancer Res; 2017 May; 23(10):2405-2413. PubMed ID: 27821605
[No Abstract] [Full Text] [Related]
2. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Shapiro GI; McCallum S; Adams LM; Sherman L; Weller S; Swann S; Keer H; Miles D; Müller T; Lorusso P
Invest New Drugs; 2013 Jun; 31(3):742-50. PubMed ID: 23054208
[TBL] [Abstract][Full Text] [Related]
3. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Chia SK; Ellard SL; Mates M; Welch S; Mihalcioiu C; Miller WH; Gelmon K; Lohrisch C; Kumar V; Taylor S; Hagerman L; Goodwin R; Wang T; Sakashita S; Tsao MS; Eisenhauer E; Bradbury P
Breast Cancer Res; 2017 May; 19(1):54. PubMed ID: 28464908
[TBL] [Abstract][Full Text] [Related]
4. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
[TBL] [Abstract][Full Text] [Related]
5. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
Shah MA; Wainberg ZA; Catenacci DV; Hochster HS; Ford J; Kunz P; Lee FC; Kallender H; Cecchi F; Rabe DC; Keer H; Martin AM; Liu Y; Gagnon R; Bonate P; Liu L; Gilmer T; Bottaro DP
PLoS One; 2013; 8(3):e54014. PubMed ID: 23516391
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Seiwert T; Sarantopoulos J; Kallender H; McCallum S; Keer HN; Blumenschein G
Invest New Drugs; 2013 Apr; 31(2):417-24. PubMed ID: 22918720
[TBL] [Abstract][Full Text] [Related]
8. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
[TBL] [Abstract][Full Text] [Related]
10. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
11. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
Rayson D; Lupichuk S; Potvin K; Dent S; Shenkier T; Dhesy-Thind S; Ellard SL; Prady C; Salim M; Farmer P; Allo G; Tsao MS; Allan A; Ludkovski O; Bonomi M; Tu D; Hagerman L; Goodwin R; Eisenhauer E; Bradbury P
Breast Cancer Res Treat; 2016 May; 157(1):109-16. PubMed ID: 27116183
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
Naing A; Kurzrock R; Adams LM; Kleha JF; Laubscher KH; Bonate PL; Weller S; Fitzgerald C; Xu Y; LoRusso PM
Invest New Drugs; 2012 Feb; 30(1):327-34. PubMed ID: 20842406
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
Singh RP; Patel B; Kallender H; Ottesen LH; Adams LM; Cox DS
J Clin Pharmacol; 2015 Oct; 55(10):1184-92. PubMed ID: 25998042
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.
Boige V; Malka D; Bourredjem A; Dromain C; Baey C; Jacques N; Pignon JP; Vimond N; Bouvet-Forteau N; De Baere T; Ducreux M; Farace F
Oncologist; 2012; 17(8):1063-72. PubMed ID: 22707516
[TBL] [Abstract][Full Text] [Related]
15. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
[TBL] [Abstract][Full Text] [Related]
16. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
17. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
Zillhardt M; Park SM; Romero IL; Sawada K; Montag A; Krausz T; Yamada SD; Peter ME; Lengyel E
Clin Cancer Res; 2011 Jun; 17(12):4042-51. PubMed ID: 21551255
[TBL] [Abstract][Full Text] [Related]
18. First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.
Hu X; Zheng X; Yang S; Wang L; Hao X; Cui X; Ding L; Mao L; Hu P; Shi Y
J Hematol Oncol; 2020 Jan; 13(1):6. PubMed ID: 31948451
[TBL] [Abstract][Full Text] [Related]
19. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
[TBL] [Abstract][Full Text] [Related]
20. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
